Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234177 · ClinicalTrials.gov registry record
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
A clinical trial of Colorectal Cancer, sponsored by Tempus AI.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT05234177 is a study of Colorectal Cancer that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 300 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05234177, a study of Colorectal Cancer, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Conditions Studied
Interventions
- OTHER Observation
Study Locations (20)
Missouri
- Mercy Clinic Oncology and Hematology - Joplin - Joplin
- Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center - Springfield
- Washington University School of Medicine - St Louis
- Mercy Clinic Oncology and Hematology - Sindelar Cancer Center - St Louis
- Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center - St Louis
Ohio
- Aultman Hospital - Canton
- TriHealth Cancer Institute - Cincinnati
- Ohio State University - Columbus
- OhioHealth Research Institute - Columbus
- Toledo Clinic Cancer Center - Toledo
Arkansas
- Mercy Clinic Oncology - Fort Smith - Fort Smith
California
- MemorialCare - Fountain Valley
Maryland
- The Center for Cancer and Blood Disorders - Bethesda
Nebraska
- Nebraska Cancer Specialists - Omaha
North Carolina
- Southeastern Medical Oncology Center - Goldsboro
Oklahoma
- Mercy Clinic Oncology and Hematology - Coletta - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2029-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05234177
The ClinicalTrials.gov registry entry for NCT05234177 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT05234177 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Missouri, Ohio, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05234177 about?
NCT05234177 is a clinical study titled "Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays". The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
What is the current status of trial NCT05234177?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2022-06-21. Estimated completion is 2029-02.
What conditions does trial NCT05234177 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT05234177?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05234177?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05234177 being conducted?
This trial has 20 study locations across Arkansas, California, Maryland, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.